MD Anderson Research Highlights for February 10, 2025
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This issue includes studies to be presented this week at the 2025 American Society of Clinical Oncology (...
MD Anderson Research Highlights for February 21, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ESMO: Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers
ABSTRACTS: 2359O, 2362MO
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses...
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated positive results from the targeted therapy erdafitinib for patients with multiple tumor types harboring FGFR alterations. The data are being presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Erdafitinib is an oral medication that blocks the activity...
MD Anderson Research Highlights for May 24, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses...
MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD...
Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical...
Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations
Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in...